^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Esophageal Squamous Cell Carcinoma |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
Excerpt:
...Be able to provide tissue samples for biomarkers analysis, such as PD-L1 expression....
Trial ID:
Source:
Title:
Case Report: Immune Checkpoint Inhibitors Successfully Controlled Asymptomatic Brain Metastasis in Esophageal Squamous Cell Carcinoma
Published date:
03/01/2022
Excerpt:
...we report a rare case of ESCC with asymptomatic brain metastasis. The combined positive score (CPS) of programmed cell death-ligand 1 (PD-L1) from the primary tumor was 2 by DAKO 22C3 and 3 by VENTANA SP263....Given that his ESCC was positive for PD-L1, toripalimab, one of ICIs, was recommended for his asymptomatic solitary brain metastasis. From August 2019 to October 2020, he received 15 3-week cycles of toripalimab. A follow-up brain MRI revealed that the brain metastasis was replaced by a necrotic area (Figure 2)....By the last revision of this article, the patient was still on toripalimab with a stable disease at the primary site as well as a good cognitive function.
DOI:
https://doi.org/10.3389/fimmu.2022.746869
